BioMarin Pharmaceuticals BMRN Other operating expenses
Other operating expenses at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherOperatingIncomeExpenseNet.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's other operating expenses?
- BioMarin Pharmaceuticals (BMRN) reported other operating expenses of $3.96M in Q1 2026.
- How has BioMarin Pharmaceuticals's other operating expenses changed year-over-year?
- BioMarin Pharmaceuticals's other operating expenses increased by 302.7% year-over-year, from -$1.95M to $3.96M.
- What is the long-term trend for BioMarin Pharmaceuticals's other operating expenses?
- Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's other operating expenses has grown at a -6.6% compound annual growth rate (CAGR), from $11.85M to $9M.
- What does other operating expenses mean?
- The sum of all operational costs not categorized as R&D, sales, or production expenses.
- How do you interpret other operating expenses?
- An increase may indicate rising overhead or inefficient administrative spending, while a decrease suggests better cost control.
- How does other operating expenses compare across companies?
- Peers in the biotech sector typically keep this low; high values may signal poor expense classification or excessive administrative bloat.